A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants

Inclusion criteria

• Participant has provided informed consent.
• Participants must be a resident in mainland China, and of Chinese ancestry (participants whose parents within 3 generations are of Chinese ancestry).
• Male or female participants, between 18 and 60 years of age (inclusive). Female participants must be of nonchildbearing potential.
• In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations.
• Body mass index between 18 and 27 kg/m^2 (inclusive) and minimum weight of 55 kg .

Exclusion criteria

• History or evidence of clinically significant disorder, condition, or disease.
• History of diabetes. (regardless of type with the exception of history of gestational diabetes). Hemoglobin A1C greater than or equal to 6.5% (greater than or equal to 48 mmol/mol).
• Fasting glucose level (after at least an 8-hour fast) > 126 mg/dL (> 7 mmol/L).
• History of or ongoing hearing impairment.
• History of any autoimmune disease, inflammatory bowel disease, or TED.
• History or evidence of ECG-findings.
• Systolic blood pressure ≥ 140 mmHg or < 90 mmHg, or diastolic blood pressure ≥ 90 mmHg or < 50 mmHg, or pulse > 100 bpm or < 50 bpm , at screening or check-in.
• History of relevant drug and/or food allergies.
• Poor peripheral venous access and/or unable to receive IV infusion therapy.
• Estimated glomerular filtration rate less than 90 mL/min/1.73 m2.
• Active liver disease or hepatic dysfunction.
• History of a medical condition associated with an increased risk of bleeding.
• History of any major surgery within 6 months.
• History of alcoholism or drug/chemical abuse within 1 year prior to check-in.
• Use of tobacco- or nicotine-containing products within 6 months prior to check-in.
• Positive test for illicit drugs and/or tetrahydrocannabinol/cannabinoids at check-in.
• Female participants with a positive serum pregnancy test.
• Female participants who are lactating/breastfeeding.
• Male participants with partners who are pregnant.
• Unwilling to adhere to contraceptive requirements.
• Participant has received a dose of an investigational drug within the past 90 days.
• Have previously completed or withdrawn from this study or any other study investigating teprotumumab or have previously received the investigational product.